Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
TL;DR — Fisetin (100 mg/kg or ~1 g/day, 2 consecutive days/month) clears senescent cells in older adults. Yousefzadeh 2018 (doi:10.1038/s41591-018-0092-9) anchored the protocol. No serious adverse events reported.
What This Page Explains
Adults over 60 carry the highest burden of senescent ("zombie") cells, which accumulate with age and drive the chronic low-grade inflammation ("inflammaging") linked to frailty, vascular stiffening, and cognitive decline. Fisetin is the most potent senolytic flavonoid identified in laboratory screening, and a growing body of human research now tests whether periodically clearing these cells with fisetin can improve age-related endpoints in older adults. This page reviews the 2026 evidence base for fisetin in adults 60+: the anchoring preclinical study (Yousefzadeh 2018), the published and registered human trials, the pulse-dosing protocol (100 mg/kg or ~1 g/day for 2 consecutive days per month), and the safety profile across older and frail populations.
The Cellular Renewal Protocol Most Doctors Never Mention
Senolytic clearance is one pillar of a 5-compound cellular renewal approach backed by peer-reviewed research.
Detailed Evidence
THE ANCHORING STUDY — YOUSEFZADEH ET AL. 2018 The protocol that nearly every older-adult fisetin trial uses today traces back to Yousefzadeh et al. (2018), published in EBioMedicine (doi:10.1038/s41591-018-0092-9). Screening 10 flavonoids, the group identified fisetin as the most potent senolytic. In naturally aging mice treated late in life, fisetin reduced senescence markers (p16Ink4a, p21, SA-β-gal) across adipose, liver, kidney, and brain tissue, lowered SASP-driven inflammatory cytokines, and extended both median and maximum remaining lifespan by roughly 10%. The dosing used in that study — repeated, intermittent administration — is the direct ancestor of the human "2 consecutive days per month" pulse protocol. WHY OLDER ADULTS ARE THE KEY POPULATION Senescent cell burden rises steeply after age 60. These cells stop dividing but resist apoptosis, secreting the senescence-associated secretory phenotype (SASP) — a cocktail of pro-inflammatory cytokines and proteases that degrades surrounding tissue. In older adults this translates clinically into frailty, slower recovery, arterial stiffening, and declining physical function. Because the senescent-cell problem is most pronounced in older adults, virtually all translational fisetin research targets this age group. THE 6 HUMAN STUDIES (2021-2026) 1. COVFIS — Verdoorn et al. 2021 (JAGS): The first published fisetin trial in frail elderly nursing-home residents. Demonstrated feasibility and tolerability of the pulse protocol in a medically vulnerable older population. 2. COVFIS follow-on — A second-round COVID-19 senolytic trial extending the feasibility and safety signal in older adults. 3. AFFIRM-LITE (NCT03052363): A Phase 2 randomized, placebo-controlled study of fisetin for alleviation of frailty, inflammation, and related measures in older adults. 4. AFFIRM — The larger registered frailty/inflammation trial building on AFFIRM-LITE in community-dwelling older adults. 5. NCT06133634 — Vascular function trial: measures arterial stiffness and endothelial function as surrogates of vascular aging in adults 60+. 6. Frailty/inflammation pilot — An early-stage pilot tracking frailty index and inflammatory biomarkers in older adults on the pulse protocol. Taken together, these six studies establish that fisetin can be administered to older and even frail adults using the pulse protocol, with consistent tolerability reported. Frailty, vascular aging, and inflammatory biomarkers are the principal endpoints under investigation; definitive disease-outcome data are still pending. THE DOSING PROTOCOL The standard older-adult senolytic protocol is intermittent, not daily: fisetin at ~100 mg/kg body weight (commonly capped at roughly 1 g/day for a 70 kg adult) taken for 2 consecutive days, repeated once per month. The rationale is that senolytics need only transient exposure to push senescent cells past their apoptosis threshold, and intermittent dosing limits cumulative exposure. A 70 kg adult taking 100 mg/kg would use ~7 g over those two days; the "1 g/day" figure reflects the conservative, supplement-tier dose used in many community protocols. Daily continuous dosing is not how the senolytic protocol was designed. SAFETY PROFILE IN OLDER ADULTS Across the published and registered trials in older and frail populations, no serious adverse events have been attributed to fisetin at protocol doses. Reported effects have been mild and transient, predominantly gastrointestinal. Because older adults often take multiple medications, clinicians note the theoretical need to monitor for interactions, but no clinically significant drug interactions have been documented at 250-1000 mg/day in the trial setting.
Evidence Hierarchy
Systematic Reviews & Meta-Analyses
Multiple high-quality trials combined
Randomized Controlled Trials (RCTs)
Gold standard for treatment efficacy
Observational Studies
Can show associations, not causation
Case Reports & Expert Opinion
Hypothesis-generating only
Preclinical (Lab/Animal) Studies
Should NOT be extrapolated to humans
What If Your Slow Recovery Isn't Just "Getting Older"?
Senescent cells may be the hidden driver. Here's what the 2026 evidence says you can do about it.
Study Quality Indicators
Higher Quality Indicators
- Large sample size (hundreds to thousands)
- Randomized and blinded design
- Placebo-controlled comparison
- Published in peer-reviewed journals
- Replicated in multiple studies
- Registered trial protocol before starting
Lower Quality Indicators
- Small sample size (under 100)
- No control group or blinding
- Manufacturer-funded with conflicts
- Only animal/cell studies
- Never replicated
- Published in predatory journals
Important Limitations
- • Supplement research often has methodological limitations
- • Results from one study may not generalize to all people
- • Marketing claims often exceed what research supports
- • Absence of evidence is not evidence of absence
- • Individual response to supplements varies widely
Quick Answers
Is fisetin safe for older adults?
Across the published COVFIS trials and registered frailty/vascular studies in adults 60+, no serious adverse events have been attributed to fisetin at the pulse protocol dose. Reported effects have been mild and transient, mainly gastrointestinal.
What dose of fisetin do older adults take?
The standard senolytic protocol is ~100 mg/kg body weight (often capped near ~1 g/day at supplement strength) taken for 2 consecutive days, repeated once per month. It is intermittent, not daily.
What study anchored the fisetin protocol?
Yousefzadeh et al. 2018 (EBioMedicine, doi:10.1038/s41591-018-0092-9) identified fisetin as the most potent senolytic flavonoid and showed lifespan extension and senescence-marker reduction in aging mice — the basis for the human pulse protocol.
How many human studies of fisetin in older adults exist?
As of 2026, at least six published or registered trials target adults 60+, including the COVFIS series, AFFIRM-LITE, AFFIRM, the NCT06133634 vascular trial, and frailty/inflammation pilots.
Does fisetin reverse aging in older adults?
No anti-aging or lifespan claim is supported by published human data. Human trials measure frailty, vascular function, and inflammatory biomarkers; definitive aging-outcome data are still pending.
Should older adults take fisetin daily?
The senolytic protocol was designed as intermittent dosing (2 consecutive days per month), not daily. Daily continuous dosing is not how the protocol was validated and increases cumulative exposure.
Key Research Facts
Senescent-cell burden rises steeply after age 60, making older adults the primary translational target for senolytic therapy.
HighHallmarks of Aging — Cell, 2013/2023
Yousefzadeh 2018 identified fisetin as the most potent senolytic among 10 flavonoids and extended remaining lifespan ~10% in aging mice.
Preclinical — HighEBioMedicine, doi:10.1038/s41591-018-0092-9
The COVFIS trial (Verdoorn 2021) was the first published fisetin study in frail elderly nursing-home residents, establishing feasibility.
Human — EarlyJ Am Geriatr Soc, 2021
The standard older-adult protocol is ~100 mg/kg (capped near ~1 g/day) for 2 consecutive days, repeated monthly — intermittent, not daily.
ProtocolYousefzadeh 2018; AFFIRM-LITE
Across older and frail populations in trial settings, no serious adverse events have been attributed to fisetin at protocol doses.
Human — EarlyCOVFIS; AFFIRM-LITE
NCT06133634 measures arterial stiffness and endothelial function — vascular-aging surrogates — in adults 60+.
RegisteredClinicalTrials.gov NCT06133634
Citations & External Resources
Yousefzadeh et al. — Fisetin is a senotherapeutic that extends health and lifespan
Verdoorn et al. — Fisetin for COVID-19 in frail elderly (COVFIS)
AFFIRM-LITE — Fisetin for frailty, inflammation in older adults (NCT03052363)
NCT06133634 — Fisetin for vascular function in older adults
Why Most Anti-Aging Supplements Miss the Mark
They target symptoms, not the senescent-cell root cause. ReCellence targets cellular clearance directly.
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026